Генетические аспекты формирования неалкогольной жировой болезни печени
Аннотация
Прогрессирование неалкогольной жировой болезни печени (НАЖБП) определяется генетической восприимчивостью, факторами окружающей среды, образом жизни и особенностями метаболического синдрома, многие из которых пересекаются с гепатоцеллюлярной карциномой. Тем не менее многофакторная природа НАЖБП и ограниченное количество достаточно мощных исследований являются одними из текущих ограничений для подтвержденных биомаркеров клинической полезности. Дальнейшие исследования, включающие связи между циркадной регуляцией и печеночным метаболизмом, могут представлять дополнительное направление в поиске прогностических биомаркеров прогрессирования заболеваний печени и результатов лечения.
Список литературы
1. Masarone M., Federico A., Abenavoli L. et al. Non alcoholic fatty liver: epidemiology and natural history // Rev Recent Clin Trials. 2014; 9: 126-133.
2. Loomba R., Sanyal A. J. The global NAFLD epidemic // Nat Rev Gastroenterol Hepatol. 2013; 10: 686-690.
3. Brunt E. M. Pathology of nonalcoholic fatty liver disease // Nat Rev Gastroenterol Hepatol. 2010; 7: 195-203.
4. Adams L. A., Lymp J. F., St. Sauver J. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study // Gastroenterology. 2005; 129: 113-121.
5. Patton H. M., Sirlin C., Behling C. et al. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research // J Pediatr Gastroenterol Nutr. 2006; 43: 413-427.
6. Schwimmer J. B., Newton K. P., Awai H. I. et al. Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease // Aliment Pharmacol Ther. 2013; 38: 1267-1277.
7. Schwimmer J. B., Pardee P. E., Lavine J. E. et al. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease // Circulation. 2008; 118: 277-283.
8. Williams C. D., Stengel J., Asike M. I. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study // Gastroenterology. 2011; 140: 124-131.
9. Vernon G., Baranova A., Younossi Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults // Aliment Pharmacol Ther. 2011; 34: 274-285.
10. Donnelly K. L., Smith C. I., Schwarzenberg S. J. et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease // J. Clin. Invest. 2005; 115: 1343-1351.
11. Kohjima M., Enjoji M., Higuchi N. et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease // Int. J. Mol. Med. 2007; 20: 351-358.
12. Yang Z. X., Shen W., Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease // Hepatol. Int. 2010; 4: 741-748.
13. Dentin R., Benhamed F., Hainault I. et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice // Diabetes. 2006; 55: 2159-2170.
14. Naik A., Beliс A., Zanger U. M. et al. Molecular interactions between NAFLD and xenobiotic metabolism // Front. Genet. 2013; 4: 2.
15. Dubuquoy C., Robichon C., Lasnier F. et al. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes // J. Hepatol. 2011; 55: 145-153.
16. Basantani M. K., Sitnick M. T., Cai L. et al. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome // J. Lipid Res. 2011; 52: 318-329.
17. Kotronen A., Johansson L. E., Johansson L. M. et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans // Diabetologia. 2009; 52: 1056-1060.
18. Speliotes E. K., Yerges-Armstrong L. M., Wu J. et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease // Hepatology. 2010; 51: 1209-1217.
19. Kawaguchi T., Sumida Y., Umemura A. et al. Japan Study Group of Nonalcoholic Fatty Liver, Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese // PLoS One. 2012; 7: e38322.
20. Zain S. M., Mohamed R., Mahadeva S. et al. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease // Hum. Genet. 2012; 131 (7): 1145-1152.
21. Takeuchi Y., Ikeda F., Moritou Y. et al. The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis // J. Gastroenterol. 2012; 48 (3): 405-412.
22. Namikawa C., Shu-Ping Z., Vyselaar J. R. et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis // J. Hepatol. 2004; 40: 781-786.
23. Al-Serri A., Anstee Q. M., Valenti L. et al. The sod2 c47t polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studie // J. Hepatol. 2011; 56 (2): 448-454.
24. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors // Cytokine Growth Factor Rev. 2003; 14: 185-191.
25. Antuna-Puente B., Feve B., Fellahi S. et al. Adipokines: the missing link between insulin resistance and obesity // Diabetes Metab. 2008; 34: 2-11.
26. Valenti L., Fracanzani A. L., Dongiovanni P. et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease // Gastroenterology. 2002; 122: 274-280.
27. Trujillo-Murillo K., Bosques-Padilla F. J., Calderуn-Lozano I. et al. Association of tumor necrosis factor ? and manganese superoxide dismutase polymorphisms in patients with non-alcoholic steatohepatitis from northeast Mexico // Open Hepatol. J. 2011; 3: 1-6.
28. Noga A. A., Zhao Y., Vance D. E. An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins // J. Biol. Chem. 2002; 277: 42358-42365.
29. Karavia E. A., Papachristou D. J., Kotsikogianni I. et al. Deficiency in apolipoprotein E has a protective effect on diet-induced nonalcoholic fatty liver disease in mice // FEBS J. 2011; 278 (17): 3119-3129.
30. Sazci A., Akpinar G., Aygun C. et al. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis // Dig. Dis. Sci. 2008; 53: 3218-3224.
31. Holland W. L., Miller R. A., Wang Z. V. et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin // Nat. Med. 2011; 17: 55-63.
32. Musso G., Gambino R., De Michiel F. et al. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH // Hepatology. 2008; 47: 1167-1177.
33. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors // Endocr. Rev. 2005; 26: 439-451.
34. Rui L., Yuan M, Frantz D. et al. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2 // J. Biol. Chem. 2002; 277: 42394-42398.
35. Vanni E., Bugianesi E., Kotronen A. et al. From the metabolic syndrome to NAFLD or vice versa? // Dig. Liver Dis. 2010; 42: 320-330.
36. Takahashi Y. Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver // Endocr. J. 2012; 59: 955-962.
37. Nishizawa H., Takahashi M., Fukuoka H. et al. GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model // Biochem. Biophys. Res. Commun. 2012; 423: 295-300.
38. Hong J. W., Kim J. Y., Kim Y. E. et al. Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men // Horm. Metab. Res. 2011; 43: 48-54.
39. Takahashi Y., Iida K., Takahashi K. et al. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency // Gastroenterology. 2012; 132: 938-943.
40. Korenсiс A., Bordyugov G., Ko?ir R. et al. The interplay of cis-regulatory elements rules circadian rhythms in mouse liver // PLoS One. 2012; 7: e46835.
41. Valekunja U. K., Edgar R. S., Oklejewicz M. et al. Histone methyltransferase MLL3 contributes to genome-scale circadian transcription // Proc. Natl. Acad. Sci. U.S.A. 2013; 110 (4): 1554-1559.
42. Green C. B., Takahashi J. S., Bass J. The meter of metabolism // Cell. 2008; 134: 728-742.
43. Aсimoviс J., Ko?ir R., Kastelec D. et al. Circadian rhythm of cholesterol synthesis in mouse liver: a statistical analysis of the post-squalene metabolites in wild-type and Crem-knock-out mice // Biochem. Biophys. Res. Commun. 2011; 408: 635-641.
44. Ko?ir R., Zmrzljak U. P., Bele T. et al. Circadian expression of steroidogenic cytochromes P450 in the mouse adrenal gland-involvement of cAMP-responsive element modulator in epigenetic regulation of Cyp17a1 // FEBS J. 2012; 279: 1584-1593.
45. Sahar S., Sassone-Corsi P. Metabolism and cancer: the circadian clock connection // Nat. Rev. Cancer. 2009; 89: 886-896.
46. Hirota T., Lee J. W., St John P. C. et al. Identification of small molecule activators of cryptochrome // Science. 2012; 337: 1094-1097.
47. Barclay J. L., Husse J., Bode B. et al. Circadian desynchrony promotes metabolic disruption in a mouse model of shiftwork // PLoS One. 2012; 7: e37150.
48. Husse J., Hintze S. C., Eichele G. et al. Circadian clock genes Per1 and Per2 regulate the response of metabolism-associated transcripts to sleep disruption // PLoS One. 2012; 7: e52983.
49. Froy O. The circadian clock and metabolism // Clin. Sci (Lond.). 2011; 120: 65-72.
50. Dochi M., Suwazono Y., Sakata K. et al. Shift work is a risk factor for increased total cholesterol level: a 14-year prospective cohort study in 6886 male workers // Occup. Environ. Med. 2009; 66: 592-597.
51. Konturek P. C., Brzozowski T., Konturek S. J. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options // J. Physiol. Pharmacol. 2011; 62: 591 599.
52. Chen P., Kakan X., Zhang J. Altered circadian rhythm of the clock genes in fibrotic livers induced by carbon tetrachloride // FEBS Lett. 2010; 584: 1597-1601.
53. Filipski E., Subramanian P., Carriиre J. et al. Circadian disruption accelerates liver carcinogenesis in mice // Mutat. Res. 2009; 680: 95-105.
54. Sookoian S., Castaсo G., Gemma C. et al. Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease // World J. Gastroenterol. 2007; 13: 4242-4248.
Рецензия
Для цитирования:
Ахмедов В.А., Меликов Т.И. Генетические аспекты формирования неалкогольной жировой болезни печени. Лечащий Врач. 2019;(8):28.
For citation:
Akhmedov V.A., Melikov T.I. Genetic aspects of non-alcoholic fatty liver disease development. Lechaschi Vrach. 2019;(8):28. (In Russ.)
Просмотров: 80
Послать статью по эл. почте 
